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OBJECTIVE — Albuminuria and impaired glomerular ﬁltration rate (GFR) are each associ-
ated with poor health outcomes among individuals with diabetes. Joint associations of albumin-
uria and impaired GFR with mortality have not been comprehensively evaluated in this
population.
RESEARCHDESIGNANDMETHODS — ThisisacohortstudyamongCardiovascular
Health Study participants with diabetes, mean age 78 years. GFR was estimated using serum
cystatin C and serum creatinine. Albumin-to-creatinine ratio (ACR) was measured in single-
voided urine samples.
RESULTS — Of 691 participants, 378 died over 10 years of follow-up. Cystatin C–estimated
GFR 60 ml/min per 1.73 m
2, creatinine-based estimated GFR 60 ml/min per 1.73 m
2, and
urine ACR 30 mg/g were each associated with increased mortality risk with hazard ratios of
1.73 (95% CI 1.37–2.18), 1.54 (1.21–1.97), and 1.73 (1.39–2.17), respectively, adjusting for
age, sex, race, diabetes duration, hypoglycemic medications, hypertension, BMI, smoking, cho-
lesterol, lipid-lowering medications, prevalent cardiovascular disease (CVD), and prevalent
heart failure. Cystatin C–estimated GFR and urine ACR were additive in terms of mortality risk.
Cystatin C–estimated GFR predicted mortality more strongly than creatinine-based estimated
GFR.
CONCLUSIONS — AlbuminuriaandimpairedGFRwereindependent,additiveriskfactors
for mortality among older adults with diabetes. These ﬁndings support current recommenda-
tions to regularly assess both albuminuria and GFR in the clinical care of patients with diabetes;
a focus on interventions to prevent or treat CVD in the presence of albuminuria, impaired GFR,
or both; and further consideration of cystatin C use in clinical care.
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idney disease is a major complication
of diabetes that markedly increases
risk of cardiovascular disease (CVD)
and mortality. Albuminuria, which is be-
lievedtoreﬂecthemodynamicdisturbances
within the glomerulus, has long been iden-
tiﬁed as a major prognostic indicator in in-
dividuals with diabetes (1,2). Impaired
glomerular ﬁltration rate (GFR), a comple-
mentary sign of kidney damage, is also as-
sociated with increased risk (2,3). As a
result, screening for kidney disease using
urinary albumin and serological markers of
kidney function has become a cornerstone
of diabetes care, facilitating targeted inter-
ventions to prevent CVD and kidney dis-
ease progression (4).
Albuminuria and impaired GFR may
provide additive prognostic information
regarding health outcomes in diabetes.
However, the joint association of albu-
minuriaandimpairedGFRwithmortality
has not been deﬁned in this setting, be-
cause few studies have evaluated albu-
minuria and GFR simultaneously, studies
that have reached different conclusions
(3,5), and GFR has only been estimated
using serum creatinine. GFR estimated
from serum cystatin C may reﬂect kidney
function more precisely than GFR esti-
mated using traditional serum creatinine-
based methods and is more strongly
linked with adverse health outcomes in
community-based, mostly nondiabetic
populations (6,7).
We examined associations of cystatin
C–estimated GFR, creatinine-estimated
GFR, change in estimated GFR over time,
and albuminuria with mortality among
older adults with diabetes. The relation-
ship of kidney disease with mortality may
be particularly important among older
adults. In the general population, tradi-
tional cardiovascular risk factors predict
CVD weakly in older compared with
younger adults, and the prognostic value
of kidney disease is increased (8). Our
aim was to assess whether cystatin C–
estimated GFR would provide additive
prognostic information to urine albumin
excretion and to compare the strength of
the association with mortality with that of
creatinine-estimated GFR.
RESEARCH DESIGN AND
METHODS— The Cardiovascular
Health Study (CHS) is a prospective,
community-based cohort designed to
study risk factors for the development
and progression of CVD in individuals
aged 65 years (9). Participants were re-
cruited from four U.S. communities: For-
sythCounty,NorthCarolina;Sacramento
County, California; Washington County,
Maryland; and Pittsburgh, Pennsylvania.
Eligible participants were sampled using
Medicare eligibility lists, were not institu-
tionalized, and were expected to remain
in the area for at least 3 years. Individuals
who were wheelchair-bound in the home
or receiving hospice treatment, radiation
therapy,orchemotherapyforcancerwere
excluded. The original CHS cohort of
5,201 participants was enrolled in 1989–
1990, with an additional 687 predomi-
nantly African American participants
enrolled in 1992–1993. Urine albumin
was ﬁrst measured in 1996–1997.
The current study includes CHS par-
ticipantswhoin1996–1997haddiabetes
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C, serum creatinine, and urine albumin.
At this examination, blood glucose was
measured after a 12-h fast and again 2 h
after a 75-g oral glucose load. Diabetes
was deﬁned as use of insulin or oral hy-
poglycemic agents, fasting blood glucose
126 mg/dl, and/or 2-h postchallenge
blood glucose 200 mg/dl (4). Measure-
ments of serum cystatin C, serum creati-
nine, and urine albumin were available
for 691 of 814 participants meeting the
criteria for diabetes (85%). (A full list of
the principal CHS investigators and insti-
tutions can be found at http://www.chs-
nhlbi.org/pi.htm.)
Measurements of kidney disease
Serum cystatin C was measured using a
BNII nephelometer (N Latex Cystatin C;
Dade Behring, Deerﬁeld, IL). Coefﬁcients
of variation ranged from 2.0 to 2.8% (in-
tra-assay) and from 2.3 to 3.1% (interas-
say). GFR was estimated from cystatin C
(eGFRCYS) using 1996–1997 (baseline)
measurements and the following equa-
tion: eGFRCYS  76.7  [cystatin C]
1.18
(10). Previous change in eGFRCYS over
time was calculated for each participant
using additional measurements from
1989 to 1990 and/or 1992 to 1993 and
linear regression (11). Serum creatinine
was measured in 1996–1997 (baseline)
with the Kodak Ektachem 700 Analyzer
(Eastman Kodak, Rochester, NY), which
usesacolorimetricmethod.Themeanco-
efﬁcient of variation was 1.94% (range
1.16–3.60). Serum creatinine was cali-
brated to Cleveland Clinic values using
indirect calibration to National Health
and Nutrition Examination Survey
(NHANES) III data and then was used to
estimateGFRwiththefour-variableMod-
iﬁcation of Diet in Renal Disease (MDRD)
formula (12). Estimated GFR was evalu-
ated as both a continuous and a dichoto-
mous variable ( or 60 ml/min per
1.73 m
2) (13). Urine was collected as a
single morning void. Urine albumin was
measured by rate nephelometry using the
Array 360 CE Protein Analyzer (Beckman
Instruments, Fullerton, CA). Urine creat-
inine was measured using a Kodak Ek-
tachem 700 Analyzer. Albuminuria was
quantiﬁed as urine albumin-to-creatinine
ratio (ACR), expressed in milligrams per
gram and evaluated as both a continuous
(log-transformed) and a categorical vari-
able,deﬁnedusingathresholdof30mg/g
(4,13).
Ascertainment of mortality
All-causemortalitywasascertainedbyex-
amination of death certiﬁcates, inpatient
records, nursing home or hospice records,
physician questionnaires, and autopsy re-
ports (6,7,11). For this study, partici-
pants were followed from their 1996–
1997 visit through 30 June 2006. CVD
mortality,deﬁnedasdeathfromcoronary
heart disease, myocardial infarction, sud-
den cardiac death, or stroke, was evalu-
ated as a secondary outcome.
Covariates
Covariates were measured at the 1996–
1997 CHS study visit. Race (Caucasian or
African American) and smoking status
were deﬁned by self-report. Hypoglyce-
mic medication use was classiﬁed as
none, oral medications only, or insulin
(with or without oral medications) (14).
Prevalent CVD was deﬁned as diagnoses
of coronary heart disease, stroke, or tran-
sient ischemic attack. Hypertension was
deﬁned as use of antihypertensive medi-
cations, systolic blood pressure 140
mmHg, or diastolic blood pressure 90
mmHg (15). Total cholesterol was mea-
suredusingstandardenzymaticmethods.
C-reactive protein was measured with an
enzyme-linked immunosorbent assay de-
veloped in the CHS laboratory. Duration
of diabetes was deﬁned as 4 years if the
deﬁnition of diabetes above was ﬁrst met
at the 1996–1997 CHS study visit (4).
AmongparticipantswhoenteredtheCHS
in 1989–1990, duration of diabetes was
classiﬁed as 7 years if the deﬁnition of
diabetesabovewasmetatthe1989–1990
CHS study visit and 4–7 years if it was
ﬁrst met at the 1992–93 CHS visit.
Among participants who entered in
1992–1993andhaddiabetesatthattime,
duration was classiﬁed as 7 years if du-
ration was self-reported as 3 years, and
otherwise classiﬁed as 4–7 years.
Statistical analysis
We examined the distribution of demo-
graphiccharacteristics,traditionalcardio-
vascular risk factors, prevalent CVD, and
laboratory measures by level of eGFRCYS
( or 60 ml/min per 1.73 m
2) (13). We
generated descriptive summary statistics
for each category using means  SD (or
median and interquartile range) for con-
tinuous variables and proportions for di-
chotomous variables. Within categories
of kidney disease deﬁned by estimated
GFR or urine ACR, we examined mortal-
ity rates per 100 person-years. Cox pro-
portional hazards models were used to
assess associations of kidney disease with
all-cause and cardiovascular mortality in
unadjusted and adjusted models. Covari-
ates were selected on the basis of their
biologicalplausibilitytoconfoundassoci-
ations of kidney disease and mortality.
The fully adjusted model included age,
sex, race, diabetes duration, hypoglyce-
mia medications, hypertension, BMI,
smoking, cholesterol, lipid-lowering
medications, prevalent CVD, and preva-
lent heart failure. Interaction of estimated
GFR with urine ACR was tested on the
multiplicative scale using the likelihood
ratio test and on the additive scale using
thesynergyindex.Cumulativesurvivalby
eGFRCYS and urine ACR was plotted us-
ing the Kaplan-Meier method and com-
pared using the log-rank test.
The ability of the models to discrimi-
nate between participants with and with-
out all-cause mortality was estimated by
computing the c-index, a generalization
of the c-statistic or the area under the
curve,whichallowsforcensoreddata.Be-
cause prediction models commonly show
overly optimistic performance (i.e., over-
ﬁtting) the c-index was computed with
bootstrap sampling using the Design li-
brary in S-PLUS. We also estimated the
relative contribution to global risk by
each individual measure of kidney func-
tion using the variable and model like-
lihood ratio 
2 statistic. All analyses
were performed using S-Plus (release
8.0; Insightful, Seattle, WA) and SPSS
statistical software (release 15.0.1.1;
SPSS, Chicago, IL).
RESULTS
Baseline characteristics
In 1996–1997 (baseline for this study),
mean age was 77 years, 58% of partici-
pants were female, and 19% were African
American (Table 1). Participants with
lower GFR estimated from cystatin C
(eGFRCYS) were slightly older and were
more likely to be male, to have CVD, to
smoke, and to have hypertension (Table
1). eGFRCYS was weakly correlated with
urine ACR (Pearson  0.267). Of the
participants,27%witheGFRCYS60ml/
min per 1.73 m
2 and 47% of those with
eGFRCYS  60 ml/min per 1.73 m
2 had
urine ACR 30 mg/g. eGFRCYS was
highly correlated with MDRD-estimated
GFR (eGFRMDRD, 0.762). eGFRMDRD
was60ml/minper1.73m
2for151par-
ticipants (22%).
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Over 10 years of follow-up, 378 partici-
pants (55%) died. The mortality rate was
7.7 per 100 person-years, and median
survival was 8.8 years.
Cystatin C versus creatinine
Lower eGFRCYS and lower eGFRMDRD
were each associated with increased risk
of mortality (Table 2). The association of
each GFR estimate with mortality was
monotonicandroughlylinear(supplemen-
tary Fig. 1, available in an online appendix
at http://care.diabetesjournals.org/cgi/
content/full/dc09-0191/DC1). However,
themagnitudeofassociationwithmortal-
ity was modestly greater for eGFRCYS
compared with eGFRMDRD, whether esti-
mated GFR was evaluated as a categorical
or continuous variable (Table 2). Results
were similar for all-cause and cardiovas-
cular mortality. GFR 60 ml/min per
1.73 m
2 estimated from cystatin C was
associated with a 73% increased risk of
mortality after full adjustment (P0.001).
When both eGFRCYS and eGFRMDRD were
included simultaneously in the fully ad-
justed model, eGFRCYS but not eGFRMDRD
wasassociatedwithincreasedriskofmor-
tality: hazard ratios (HRs) 1.21 (95% CI
1.10–1.33) and 1.00 (0.94–1.08) per 10
ml/min per 1.73 m
2, respectively. Results
were not altered by inclusion of ACE in-
hibitor use as a covariate or evaluation of
systolic and diastolic blood pressures as
continuous variables.
Table 3 represents a comparison of
the relative contributions to global mor-
tality risk made by each of the four mea-
sures of kidney disease, after accounting
for multiple covariates. eGFRCYS was the
strongest predictor of risk among these
measures, leading to a high likelihood ra-
tio and a c-index of 0.7645. Adding
eGFRCYS to a fully adjusted model that
included eGFRMDRD improved both the
model likelihood ratio and the c-statistic,
whereas adding eGFRMDRD to a fully ad-
justed model that included eGFRCYS re-
sulted in no improvement in ﬁt.
Change in cystatin C versus baseline
cystatin C
Loss of eGFRCYS before 1996–1997 was
alsoassociatedwithincreasedriskofmor-
tality,withastrengthofassociationsome-
what less than that for a single 1996–
1997 eGFRCYS measurement (Table 2).
WhenbotheGFRCYSandlossofGFRwere
included simultaneously in the fully ad-
justed model, eGFRCYS but not loss of
GFR was associated with increased risk of
mortality with HRs of 1.22 (95% CI
1.14–1.31) per 10 ml/min per 1.73 m
2
and 1.00 (0.95–1.04) per ml/min per
1.73 m
2/year, respectively. Prediction
models suggested that loss of GFR added
substantially less to mortality prediction
than a single eGFRCYS measurement, and
loss of GFR did not predict mortality
when included in a model with eGFRCYS
(Table 3). Cystatin C concentrations were
highly correlated within individuals over
time, as evidenced by a regression dilu-
tion ratio of 0.74 (95% CI 0.70–0.79).
Cystatin C and albuminuria
Elevated urine ACR was a strong predic-
tor of mortality, particularly cardiovascu-
lar mortality (Table 2). When both
eGFRCYS and urine ACR were included
simultaneously in the fully adjusted
model, each was independently associ-
ated with increased risk of mortality with
Table 1—Baseline characteristics of 691 CHS participants with diabetes by serum cystatin
C–estimated GFR
Estimated GFR
60 ml/min per
1.73 m
2
60 ml/min per
1.73 m
2
n 467 224
Cystatin C–estimated GFR (ml/min per
1.73 m
2) 80  16 45  10
Medical history
Age (years) 77  47 9  5
Sex (female) 284 (61) 116 (52)
Race (African American) 97 (21) 37 (17)
Duration of diabetes
4 years 189 (41) 88 (39)
4–7 years 60 (13) 21 (9)
7 years 218 (47) 115 (51)
CVD 150 (32) 101 (45)
Coronary heart disease 124 (27) 83 (37)
Stroke 31 (7) 24 (11)
Transient ischemic attack 20 (4) 15 (7)
Congestive heart failure 43 (9) 49 (22)
Smoking 232 (50) 122 (56)
Hypertension 280 (60) 156 (70)
Medications
Hypoglycemic medications
None 235 (50) 118 (53)
Oral medications only 183 (39) 65 (29)
Insulin 49 (11) 41 (18)
Antihypertensive medications 321 (69) 186 (83)
ACE inhibitors 94 (20) 78 (35)
Lipid-lowering medications 61 (13) 40 (18)
Physical measurements
BMI (kg/m
2) 28.2  5.0 28.9  4.9
Systolic blood pressure (mmHg) 137  20 139  20
Diastolic blood pressure (mmHg) 69  12 68  11
Laboratory measurements
Total cholesterol (mg/dl) 201  41 198  43
C-reactive protein (mg/l) 3.31 (1.48–6.64) 4.18 (2.00–7.88)
MDRD estimated GFR
Mean  SD (ml/min per 1.73 m
2) 91  22 59  17
60 ml/min per 1.73 m
2 27 (6) 124 (55)
Change in cystatin C–estimated GFR
(ml/min per 1.73 m
2/year) 1.25  2.27 2.85  2.71
Urine ACR (mg/g)
Median (interquartile range) (mg/g)* 11 (6–32) 24 (10–111)
30 mg/g 124 (27) 105 (47)
Data are means SD, n (%), or median (interquartile range).
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ml/min per 1.73 m
2 and 1.11 (1.04–
1.20) per doubling, respectively. Urine
ACR added to prediction of mortality
withorwithoutsimultaneousinclusionof
eGFRCYS, as demonstrated by likelihood
ratios and a change in the c-statistic (Ta-
ble 3). Urine ACR and eGFRCYS were ad-
ditive in regard to mortality risk.
Speciﬁcally, a reduction in cumulative
survival among participants with low
eGFRCYS was nearly identical to that for
participantswithelevatedurineACR,and
this reduction was approximately dou-
bled among participants with both low
eGFRCYS and elevated urine ACR (Fig. 1).
Compared with participants with normal
eGFRCYS (60 ml/min per 1.73 m
2) and
normal urine ACR (30 mg/g), fully ad-
justed HRs for mortality were 1.69 (95%
CI 1.26–2.27) for impaired eGFRCYS
(60 ml/min per 1.73 m
2) and normal
urine ACR, 1.67 (1.23–2.28) for normal
low eGFRCYS and elevated urine ACR
(30 mg/g), and 2.54 (1.88–3.44) for
bothloweGFRCYSandelevatedurineACR.
There was no interaction on the multiplica-
tive scale (interaction P0.634) or the ad-
ditive scale (synergy index 1.14 [95% CI
0.48–1.79]).
CONCLUSIONS — Albuminuria and
impaired GFR were independent, addi-
tive risk factors for mortality among older
adultswithdiabetes.GFRestimatedusing
serum cystatin C was more strongly asso-
Table 2—Associations of kidney disease with mortality among 691 CHS participants with diabetes
Total mortality CV mortality
Events
(n)
Mortality
rate*
Relative risk Events
(n)
Mortality
rate*
Relative risk
Model 1† Model 2‡ Model 1† Model 2‡
Cystatin C–estimated GFR
60 ml/min per 1.73 m
2 217 6.0 1.00 (ref) 1.00 (ref) 94 2.6 1.00 (ref) 1.00 (ref)
60 ml/min per 1.73 m
2 161 12.2 1.81 (1.45–2.25) 1.73 (1.37–2.18) 75 5.7 2.00 (1.45–2.77) 1.71 (1.21–2.42)
Per 10 ml/min per 1.73 m
2
lower estimated GFR
1.23 (1.15–1.30) 1.22 (1.14–1.30) 1.26 (1.15–1.38) 1.21 (1.10–1.33)
MDRD-estimated GFR
60 ml/min per 1.73 m
2 276 6.9 1.00 (ref) 1.00 (ref) 125 3.1 1.00 (ref) 1.00 (ref)
60 ml/min per 1.73 m
2 102 11.0 1.62 (1.28–2.04) 1.54 (1.21–1.97) 44 4.7 1.56 (1.10–2.22) 1.36 (0.94–1.96)
Per 10 ml/min per 1.73 m
2
lower estimated GFR
1.13 (1.08–1.18) 1.12 (1.07–1.17) 1.14 (1.06–1.22) 1.11 (1.03–1.18)
Loss of cystatin C–estimated
GFR§
3 ml/min per 1.73 m
2/year 271 7.0 1.00 (ref) 1.00 (ref) 113 2.9 1.00 (ref) 1.00 (ref)
3 ml/min per 1.73 m
2/year 107 10.4 1.66 (1.30–2.11) 1.57 (1.22–2.01) 56 5.5 2.07 (1.46–2.92) 1.85 (1.29–2.65)
Per ml/min per 1.73 m
2/year
decrease in estimated GFR
1.07 (1.02–1.12) 1.06 (1.01–1.10) 1.10 (1.04–1.17) 1.07 (1.01–1.13)
Urine ACR
30 mg/g 214 6.0 1.00 (ref) 1.00 (ref) 86 2.4 1.00 (ref) 1.00 (ref)
30 mg/g 164 12.0 1.88 (1.52–2.32) 1.73 (1.39–2.17) 83 6.1 2.32 (1.70–3.18) 1.96 (1.40–2.73)
Per doubling 1.22 (1.15–1.30) 1.18 (1.10–1.26) 1.32 (1.20–1.45) 1.24 (1.12–1.37)
*Per 100 person-years. †Model 1 adjusted for age, sex, and race. ‡Model 2 adjusted for age, sex, race, diabetes duration, hypoglycemic medications, hypertension,
BMI, smoking, total cholesterol, lipid-lowering medications, prevalent cardiovascular disease, and prevalent congestive heart failure. §Loss of glomerular ﬁltration
rate estimated from serum cystatin C over the 7 years preceding ascertainment of mortality. ref, referent.
Table 3—Contributions of kidney disease to prediction of total mortality among 691 CHS participants with diabetes
Likelihood ratio test
c-statistic (95% CI) Model 
2 Variable 
2 P*
Base model† 175.24 0.7385 (0.7046–0.7783)
	 Cystatin C–estimated GFR 212.14 36.90 0.001 0.7654 (0.7319–0.8026)
	 MDRD-estimated GFR 198.50 23.26 0.001 0.7550 (0.7221–0.7939)
	 Change in cystatin C–estimated GFR 180.12 4.88 0.019 0.7421 (0.7082–0.7814)
	 Urine ACR 189.82 14.58 0.009 0.7525 (0.7114–0.7844)
Base model† 	 MDRD-estimated GFR 198.50 0.7550 (0.7221–0.7939)
	 Cystatin C–estimated GFR 212.83 14.33 0.001 0.7674 (0.7319–0.8026)
Base model† 	 cystatin C–estimated GFR 212.14 0.7654 (0.7319–0.8026)
	 MDRD-estimated GFR 212.83 0.69 0.916 0.7674 (0.7319–0.8026)
	 Change in cystatin C–estimated GFR 212.24 0.10 0.834 0.7676 (0.7319–0.8026)
	 Urine ACR 219.28 7.14 0.274 0.7746 (0.7336–0.8041)
*P value tests whether model with variable differs from corresponding base model in bold. †Adjusted as per Table 2, model 2, without estimated GFR or urine ACR.
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using serum creatinine. These ﬁndings
supportcurrentrecommendationstoreg-
ularly assess both albuminuria and GFR
in the clinical care of patients with diabe-
tes(4)withasharpfocusoninterventions
to prevent or treat CVD in the presence of
albuminuria, impaired GFR, or both and
further consideration of cystatin C use in
clinical care.
The additive prognostic utilities of al-
buminuria and impaired GFR are consis-
tent with prior studies in populations
without diabetes or with low diabetes
prevalence (8,16–20). Demonstration of
this relationship in a diabetic population
is particularly useful, because this popu-
lationhasahighcardiovascularriskandis
well suited for regular health screening.
Our results are similar and complemen-
tary to those from a Hong Kong cohort in
whichassociationsofalbuminuriaandes-
timatedGFRwithincidentcardiovascular
events were assessed (3). In contrast, an
Italian study of type 2 diabetes observed
albuminuria to be the primary renal risk
factor for mortality, with estimated GFR
being an independent risk factor only at
levels 30 ml/min per 1.73 m
2 (5). Our
results may differ from results for the Ital-
ian study owing to older participant age
or to use of serum cystatin C to estimate
GFR.
In our study, 53% of participants
with impaired GFR (eGFRCYS 60 ml/
min per 1.73 m
2) had urine ACR 30
mg/g. This proportion is higher than that
observed in NHANES III, (21) possibly
because of 1) the added effects of diabetes
and advanced age on GFR and 2) more
sensitivedetectionofimpairedGFRusing
serumcystatinC.Thislargeproportionof
participants with impaired GFR but nor-
mal urine ACR is similar to that observed
in the UK Prospective Diabetes Study
(22), and, when combined with the inde-
pendent and additive associations of each
kidney disease measure with mortality,
supports the general concept that albu-
minuria and impaired GFR are separate
but overlapping, complementary mani-
festations of diabetic kidney disease. This
concept has recently emerged as an alter-
native to an earlier paradigm describing
albuminuria and impaired GFR as serial
manifestations of diabetic kidney disease
along a single, linear disease pathway
(23,24).
Thus,albuminuriaandimpairedGFR
may reﬂect different pathways of kidney
damage. Albuminuria may reﬂect wide-
spread vascular damage and endothelial
dysfunction, thus identifying susceptibil-
ity to disease in nonrenal vascular beds
(25). Impaired GFR may reﬂect loss of
nephrons and parenchymal ﬁbrosis that
leads to CVD through accumulation of
uremic toxins, impaired volume and
blood pressure regulation, and multiple
metabolic abnormalities. Whether albu-
minuria and impaired GFR lead to CVD
through distinct mechanisms, thus re-
quiring distinct interventions, has not
been established.
The association of cystatin C–esti-
mated GFR with mortality was modestly
strongerthanthatforGFRestimatedfrom
serum creatinine. This ﬁnding is consis-
tent with prior studies using the full CHS
population (6,7). These studies demon-
strated 1) that cystatin C–estimated GFR
was linearly associated with mortality
risk, whereas MDRD-estimated GFR
demonstrated a U-shaped association
withmortality,and2)thatelevatedserum
cystatin C was associated with mortality
when MDRD-estimated GFR was in the
“normal” range. It is possible that cystatin
C estimates true GFR more precisely in
thenear-normalrangeorthatcystatinCis
less susceptible to confounding by body
size among older adults. We evaluated
only one formula estimating GFR from
cystatin C, which was developed among
individuals with impaired kidney func-
tion, and other cystatin C–based formu-
las may perform differently.
In our study, a change in cystatin
C–estimatedGFRwithinindividualsover
time was not associated with mortality
more strongly than a single baseline cys-
tatin C measurement. This result may be
explained in part by the relatively high
correlation of cystatin C concentration
within individuals over time and suggests
that single cystatin C measurements carry
important prognostic information on their
own, even without prior context. However,
the value of longitudinal measurements
may be increased when more measure-
ments per individual are available.
Limitations of this study include the
availability of only a single urine ACR
measurement and lack of data assessing
current glycemic control. Notably, how-
ever, we were able to account for diabetes
duration and the use of hypoglycemic
medications,whichreﬂectcumulativeex-
posure to hyperglycemia and disease se-
verity and have been associated with
mortality in CHS (14). In addition, our
ﬁndings may not extrapolate to younger
diabetic populations. Study strengths in-
clude the diverse, community-based dia-
Figure 1—Cumulative survival by GFR estimated from serum cystatin C (milliliters per minute
per 1.73 m
2) and urine ACR (milligrams per gram) among 691 CHS participants with diabetes.
de Boer and Associates
care.diabetesjournals.org DIABETES CARE, VOLUME 32, NUMBER 10, OCTOBER 2009 1837betic population, multiple measurements
of kidney disease, long-term follow-up for
mortality and adjudicated CVD events, and
largenumbersofeventstofacilitatestudyof
kidney disease interactions.
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